Short Communication: Effect of Etanercept (Enbrel) on Interleukin 6, Tumor Necrosis Factorα, and Markers of Immune Activation in HIV-Infected Subjects Receiving Interleukin 2
| Autor: | Beverly E. Sha, Alejo Erice, Ann Namkung, Robert E. Walker, Lawrence Fox, Hernan Valdez, Alan L. Landay, Lynne Bancroft, Patrick Kilgo, Jan Agosti, Donna Mildvan, Michael M. Lederman, Richard B. Pollard, Ronald T. Mitsuyasu, Debra Ogata-Arakaki, Rebecca Gelman, Scharla Estep |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Interleukin 2
biology business.industry medicine.medical_treatment Immunology C-reactive protein Pharmacology Etanercept Infectious Diseases Cytokine Virology Blood plasma medicine biology.protein Interferon gamma Tumor necrosis factor alpha skin and connective tissue diseases Interleukin 6 business medicine.drug |
| Zdroj: | AIDS Research and Human Retroviruses. 18:661-665 |
| ISSN: | 1931-8405 0889-2229 |
| Popis: | The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on plasma cytokines was evaluated in 11 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2). Plasma IL-6 and C-reactive protein (CRP) levels increased after rhIL-2 treatment. Etanercept pretreatment attenuated these increases. Median plasma IL-6 levels were 20.29 pg/ml 4 days after rhIL-2 and 7.87 pg/ml 4 days after etanercept and rhIL-2 (p = 0.22); median CRP levels were 78.73 and 46.16 microg/ml, respectively (p = 0.03). An effect on TNF bioactivity could not be assessed as all measurements were below limits of detection. No significant changes were seen in temperature or plasma levels of IL-4, IL-10, IL-12, interferon gamma, or HIV-1 RNA levels. All subjects had undetectable or low-level HIV-1 RNA levels before etanercept dosing. One subject died; however, her death was thought to be unrelated to etanercept. Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|